Enfortumab vedotin + pembrolizumab across the bladder cancer continuum
The ADC-immunotherapy pair that doubled survival in advanced disease now also works around surgery, in fit and unfit patients alike.
EV-302 (metastatic, OS HR 0.47), EV-303 (cisplatin-ineligible MIBC, EFS HR 0.40, approved Nov 2025), EV-304 (cisplatin-eligible MIBC, positive Dec 2025). The first regimen to displace platinum chemotherapy at every stage of a common solid tumour.
Pages like this
not linked directly; found by shared links- IdeaBladder preservation for MIBC after perioperative EV + pembrolizumab complete response
Shares EV-304 / KEYNOTE-B15, EV-303 / KEYNOTE-905, Enfortumab vedotin, Bladder & urothelial cancer.
- PersonJae Lyun Lee
Shares EV-302 / KEYNOTE-A39, Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
- PersonShilpa Gupta
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
- PairingADC + checkpoint inhibitor
Shares EV-302 / KEYNOTE-A39, Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
- TargetNectin-4
Shares EV-303 / KEYNOTE-905, EV-302 / KEYNOTE-A39, Enfortumab vedotin, Bladder & urothelial cancer.
- Key paperEV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer
Shares EV-302 / KEYNOTE-A39, Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
- TechnologyADC payload neutralisers
- CompanyAstellas